Home › Drug Codes › CPT Codes › 91323 · mNEXSPIKE 2025-26 (12Y UP)
Updated July 1st, 2026

mNEXSPIKE 2025-26 (12Y UP) CPT Vaccine Code: 91323

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 10 mcg/0.2 mL dosage, for intramuscular use

Login to unlock all benchmarks
Medicare Payment Limit ?
$252.225
2026–27 Season rate · per dose
CDC Cost / Dose ?
$•••.••
Login to view
Private Sector Cost / Dose ?
$•••.••
Login to view
WAC · AWP ?
$•••.••
Login to view
NDCs Crosswalked ?
6
View NDC crosswalk →
Medicare Coverage Medicare Part B covers mNEXSPIKE 2025-26 (12Y UP) as a preventive vaccine — the Part B deductible and coinsurance do not apply.

Vaccine & Product Overview

HCPCS Descriptor Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 10 mcg/0.2 mL dosage, for intramuscular use
Manufacturer Moderna
Route of Administration Intramuscular
Generic Status Single-Source; Branded
Dosage Form Injection, Suspension

About mNEXSPIKE 2025-26 (12Y UP)

mNEXSPIKE 2025-26 (12Y UP) is a medication aligned to the HCPCS CPT Drug Code: 91323 for billing, pricing, and reimbursement purposes in the United States. It is a COVID-19 drug administered via the intramuscular route and manufactured by Moderna.

According to CMS Drug Use Information: This vaccine is used to help prevent coronavirus disease, also known as COVID-19. It works by increasing the body's natural defense (immunity) against the virus. This vaccine may prevent the illness, or reduce the seriousness of it. Vaccines may not fully protect everyone who receives them.

Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.

NDC Code Information

6 NDC packages are crosswalked to 91323. Package detail is available to logged-in subscribers.

NDC Code Drug Manufacturer Billing Units / Pkg Package Size
•••••-••••-•• Log in to view mNEXSPIKE 2025-26 (12Y UP)
mNEXSPIKE 2025-26 (12Y UP)
mNEXSPIKE 2025-26 (12Y UP)
mNEXSPIKE 2025-26 (12Y UP)
Login to view 6 NDC packages View pricing, complete NDC-to-HCPCS alignments, and package details.
Login →

mNEXSPIKE 2025-26 (12Y UP) Pricing & Reimbursement

91323 Private Payer Reimbursement
$204.57 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →
UnitedHealthcare, BlueCross BlueShield, Aetna, Cigna

Historical Graphing and Billing Calculator

per HCPCS unit
As of Q3 2026

Medicare vaccine payment limits reset each season (effective August 1) — year-over-year steps in the chart reflect the new season's pricing, not data errors.

mNEXSPIKE 2025-26 (12Y UP) Vaccine Administration Codes

The below list of CPT codes is intended for informational purposes only and may not be exhaustive. CPT® codes and descriptions are copyright American Medical Association (AMA). All rights reserved.

CPT Code Description
90471 Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), one vaccine (single or combination vaccine/toxoid)
90472 Immunization administration (each additional vaccine or toxoid), when performed in conjunction with primary procedure.

mNEXSPIKE 2025-26 (12Y UP) Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

COVID-19 caused by SARS-CoV-2
Drug Class
Actively Acquired Immunity [PE]Inactivated SARS-CoV-2 Vaccine [EPC]mRNA Vaccine [EPC]Vaccines, mRNA [CS]

Login for BuyandBill.com Analytics

Unlock deeper insights with BuyandBill’s Comparative Report!

  • Compare ASP, WAC, and AWP across drugs.
  • Visualize Drug Price Movement Over Time
  • Tailor reports to drug class, manufacturer, or HCPCS Code.
  • Compare Biosimilar and 505(b)(2) products.
Access Full Report →

Frequently Asked Questions

Is there an available mNEXSPIKE 2025-26 (12Y UP) billing and coding guide?
Billing and coding information for mNEXSPIKE 2025-26 (12Y UP) can be found through Moderna. Visit Here →
Are there any available mNEXSPIKE 2025-26 (12Y UP) patient assistance programs?
Our team has not identified a manufacturer-published source of patient assistance information for mNEXSPIKE 2025-26 (12Y UP).
Where can I find mNEXSPIKE 2025-26 (12Y UP) prescribing information?
mNEXSPIKE 2025-26 (12Y UP) prescribing information can be found at the link below. Visit Here →
Where can I find mNEXSPIKE 2025-26 (12Y UP) side effect information?
Information regarding mNEXSPIKE 2025-26 (12Y UP)'s side effects can be found at MedlinePlus. Visit Here →
Does billing mNEXSPIKE 2025-26 (12Y UP) require JZ/JW wastage modifiers?
This product is new and does not yet appear on the CMS list of HCPCS pertaining to single-dose containers.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.

Related Drug Codes

Explore billing, coding, and pricing for drugs related to mNEXSPIKE 2025-26 (12Y UP).

91319PFIZER-BIONTECH COVID-19 VACCINE 2023-2024 AGE5<12Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 10 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular usePfizer91322SPIKEVAX 2023-2024 FORMULASevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular useModerna91320COMIRNATY 2023-2024 AGE 12 AND OLDERSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular usePfizer91321COVID-19 VACCINE 2023-2024Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular useModerna91304NOVAVAX COVID-19 VACCINE, 2023-2024 ADJUVANTEDSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, 5 mcg/0.5 mL dosage, for intramuscular useNovavax91318COVID-19 VACCINE 2023-2024Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 3 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular usePfizerJ0248VEKLURYInjection, remdesivir, 1 mgGilead Sciences, IncAdded December 23, 2021Q0222BEBTELOVIMABInjection, bebtelovimab, 175 mgEli Lilly and CompanyAdded February 11, 2022Q0234TofidenceInjection, tocilizumab-bavi, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation only, 1 mgBiogenAdded July 1, 2026Q0237AvtozmaInjection, tocilizumab-anoh, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mgCelltrion USAAdded January 24, 2025